Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Inclusion Criteria

• •Histologically confirmed prostate adenocarcinoma
• •Metastatic disease
• •Able and willing to provide informed consent and to comply with the study procedures
• •Castration resistant disease defined as evidence of radiological and/or prostate specific antigen (PSA) progression despite castrate levels of testosterone (serum testosterone \< 50 ng/dL \[1.7 nmol/L\]); for PSA progression, there must be at least 2 sequential rises at a minimum of 1-week intervals; the first PSA value must be \>= 4 (Prostate Cancer Working Group 2 \[PCWG2\] criteria)
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• •At least 21 days have passed since completing radiotherapy (exception for radiotherapy: at least 7 days since completing a single fraction of =\< 800 cGy to a restricted field or limited-field radiotherapy to non-marrow bearing area such as an extremity or orbit) at the time of registration
• •At least 21 days have passed since receiving any investigational agent at the time of registration
• •At least 21 days have passed since major surgery
• •Neuropathy =\< grade 1 at the time of registration
• •Has recovered from all therapy-related toxicity to =\< grade 2 (except alopecia, anemia and any signs or symptoms of androgen deprivation therapy) at the time of registration
• •Poor prognosis disease as defined by any of the following:
• •* PSA nadir \>=4.0, or
• •* Gleason score 8-10, or
• •* Time from ADT initiation to CRPC of =\< 16 months
• •Hemoglobin \>= 90 g/L
• •Neutrophils \>= 1.5 x 10\^9 /L
• •Platelets \>= 100 x 10\^9/L
• •Aspartate aminotransferase (AST) \< 1.5 x upper limit of normal (ULN)
• •Alanine aminotransferase (ALT) \< 1.5 x ULN
• •Bilirubin =\< 1.0 x ULN (exceptions for Gilbert's syndrome)
• •Creatinine =\< 1.5 x ULN